Nasdaq rxrx
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance.Jul 17, 2023 · Clinical-stage biotechnology company Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) saw its stock double on the announcement of a $50 million investment from artificial intelligence (AI) ...
Did you know?
Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission.The fund owned 2,335,132 shares of the company's stock after selling …That's what's happening with Recursion Pharmaceuticals (NASDAQ: RXRX), an innovative biotech. The company's shares are currently changing hands for …Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing ...December 9, 2023 at 11:06 AM · 4 min read. In a notable insider transaction, CEO Christopher Gibson sold 59,829 shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) on December 6, 2023. This ...
2 days ago · Director Blake Borgeson of Recursion Pharmaceuticals Inc (NASDAQ:RXRX) has sold 20,054 shares of the company on January 23, 2024, according to a recent SEC Filing. The transaction was executed at ... Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel ...Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, ...Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo Finance.
Dec 16, 2023 · Recursion Pharmaceuticals (NASDAQ: RXRX) has built one of the world’s most advanced AI-powered platforms to help decode human biology. RXRX gathers data and experiments on millions of biological ... Platinum Investment Management Ltd. lessened its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 13.9% in the 3rd …NASDAQ:RXRX opened at $9.78 on Friday. Recursion Pharmaceuticals has a 1 year low of $4.54 and a 1 year high of $16.75. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of -6.70 and a beta of 0.63.…
Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Recursion Pharma (NASDAQ: RXRX) made waves this . Possible cause: Recursion (NASDAQ: RXRX) is a clinical stage ...
With Recursion Pharmaceuticals stock trading at $11.93 per share, the total value of Recursion Pharmaceuticals stock (market capitalization) is $2.58B. Recursion Pharmaceuticals stock was originally listed at a price of $31.30 in Apr 16, 2021. If you had invested in Recursion Pharmaceuticals stock at $31.30, your return over the last 2 years ...Sep 14, 2023 · Recursion Pharmaceuticals (NASDAQ:RXRX) was a new buy in the portfolio last week. This is a clinical-stage biotechnology company that combines experimental biology, bioinformatics, and artificial ... Recursion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RXRX updated stock price target summary.
That means RXRX is a top biotech stock capturing the overall trend rather than betting the farm on a single drug or therapeutic. And major players are taking note. Nvidia (NASDAQ: NVDA) is betting ...Jan 2, 2024 · But Recursion Pharmaceuticals (NASDAQ: RXRX) is accelerating drug discovery using artificial intelligence . This novel approach makes RXRX a top biotech stock to capture the broad longevity trend. According to the issued ratings of 4 analysts in the last year, the consensus rating for Recursion Pharmaceuticals stock is Hold based on the current 3 hold ratings and 1 buy rating for RXRX. The average twelve-month price prediction for Recursion Pharmaceuticals is $11.20 with a high price target of $15.00 and a low price target of $8.00.
an e stock Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) institutional owners may be pleased with recent gains after 14% loss over the past yearJan 19, 2024 · Financial Performance. In 2022, RXRX's revenue was $39.84 million, an increase of 291.46% compared to the previous year's $10.18 million. Losses were -$239.48 million, 28.4% more than in 2021. Financial Statements. caseypercent27s sports grill birmingham menug4 Get the latest Recursion Pharmaceuticals Inc (RXRX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment... night club cerca de mi Shares of NASDAQ:RXRX opened at $10.23 on Friday. Recursion Pharmaceuticals, Inc. has a 52 week low of $4.54 and a 52 week high of $16.75. The firm’s 50 day moving average is $9.27 and its two ...The latest price target for . Recursion Pharmaceuticals (NASDAQ: RXRX) was reported by Needham on January 17, 2024.The analyst firm set a price target for $15.00 expecting RXRX to rise to within ... bg4l7jtk2wmflexible betreuungszeitenaleman espanol traductor 3. Big pharma appears to be in the mood to collaborate. The last green flag for biotech stocks is that big pharma players like Pfizer are actively searching for businesses to collaborate with in ...Sumitomo Mitsui Trust Holdings Inc. boosted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 320.7% in the third quarter, according to the company in its most recent ... maria lvova belova SALT LAKE CITY, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to … bobpercent27s discount furniture bangoropercent27reillypercent27s on dixie highwaynoveswskimgs Shares of Recursion Pharmaceuticals ( RXRX -4.40%) sank 17.7% lower as of the market close on Wednesday. The decline came after the company provided its third-quarter update Wednesday morning ...